You are here: Industry Insights > Ionis

News List

Biogen to obtain licence for Ionis’ investigational SMA therapy Pharmaceutical-Technology
January 06, 2022
Biogen will handle the expenses associated with the development, production and potential marketing of BIIB115.
AstraZeneca, Ionis close deal on antisense therapy development pharmaceutical-business-review
December 30, 2021
under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
AstraZeneca and Ionis partner to develop antisense therapy eplontersen Pharmaceutical-Technology
December 09, 2021
AstraZeneca and Ionis Pharmaceuticals have signed an agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX.
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials europeanpharmaceuticalreview
July 30, 2021
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
Ionis Appoints Clinical Development EVP contractpharma
January 11, 2021
Eugene Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises.
Ionis and Akcea announce that Pfizer initiated clinical study of vupanorsen pharmaceutical-business-review
November 06, 2020
Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics, Inc., announced that Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol ...
Ionis Begins ALS Clinical Trial americanpharmaceuticalreview
October 28, 2020
Ionis Pharmaceuticals announced the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless ...
Ionis to Acquire Outstanding Shares of Akcea for $500M contractpharma
September 01, 2020
Ionis will benefit from Akcea's pipeline and commercial products, and further strengthens financial position to support future investments.
Akcea, Ionis Announce Initiation of Trial for Amyloid Cardiomyopathy Treatment americanpharmaceuticalreview
January 16, 2020
Akcea Therapeutics and Ionis Pharmaceuticals announced the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for AKCEA-TTR-LRx in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy).
Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics pharmaceutical-business-review
January 14, 2020
Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics. Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indicatio

Previous page 1 2 3 Next page